HCV Retreatment and Resistance

In this video module, David L. Wyles, MD, moderates an expert panel discussion of best practices and evidence-based approaches to retreatment of patients with HCV who have failed previous therapy and the role of resistance testing for these patients.
Mark S. Sulkowski, MD
Program Director
Ira M. Jacobson, MD
Mark S. Sulkowski, MD
person default
David L. Wyles, MD
Released: June 27, 2016 Expiration: No longer available for credit

Related Content

Expert selections of important viral hepatitis data from AASLD 2021, including studies of patients with HBV, HCV, and HDV (hepatitis delta virus), from Clinical Care Options (CCO)

Nancy Reau, MD Stefan Zeuzem, MD Released: November 29, 2021

Ani Kardashian, MD, discusses how social determinants of health influence liver disease prevalence, outcomes, and treatment access in the US, from Clinical Care Options (CCO)

person default Ani Kardashian, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 23, 2021 Expired: November 22, 2022

Expert commentary on incorporating lessons from the COVID-19 pandemic into improving HCV care among vulnerable populations, from Dr. Gregory Dore and Clinical Care Options (CCO)

Gregory Dore, MBBS, PhD, FRACP, MPH Released: November 8, 2021

CCO slides on the impact of racial disparities in HCV care; key strategies on recognizing and reducing inadequate HCV care in the US and globally

Prof Ashley Brown, BSc, MD, FRCP person default Ahmed M. Elsharkawy, PhD, FRCP(UK) Oluwaseun Falade-Nwulia, MBBS, MPH Joseph K. Lim, MD Released: October 11, 2021
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Bristol-Myers Squibb
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.